ERYTECH provides business update and financial results for the full year 2013 Post author:admERY Post published:April 29, 2014 Post category:Newsroom ERYTECH provides a business update and reports its financial results for the period ending December 31, 2013. You Might Also Like ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer October 4, 2021 ERYTECH Announces Withdrawal of its European Marketing Authorization Application for GRASPA for Acute Lymphoblastic Leukemia and Prepares for Resubmission November 14, 2016 ERYTECH appoints new independent board member March 26, 2015
ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer October 4, 2021
ERYTECH Announces Withdrawal of its European Marketing Authorization Application for GRASPA for Acute Lymphoblastic Leukemia and Prepares for Resubmission November 14, 2016
